Home develop
 

Keywords :   


Tag: develop

MHI, Hakata to jointly develop new container ships

2013-03-19 01:00:00| Ship Technology

Mitsubishi Heavy Industries (MHI) and Hakata Shipbuilding have signed an agreement to jointly develop a 1,000teu energy-efficient container vessel concept.

Tags: develop ships container jointly

 

Researchers at Rice University develop vanadium oxide-graphene materials for high power-density Li-ion batteries with ultrafast charging and discharging

2013-03-15 16:30:19| Green Car Congress

Tags: high university develop materials

 
 

Alstom and Adif to develop new dual-gauge rail signalling system

2013-03-15 01:00:00| Railway Technology

Alstom has signed an agreement with Spanish railway infrastructure manager Adif to develop a third rail signalling system for the Mediterranean Corridor project in Spain.

Tags: system develop rail signalling

 

Lockheed Martin to develop liquefied natural gas tanks in Louisiana, US

2013-03-14 01:00:00| Hydrocarbons Technology

US-based Lockheed Martin said that it will use its know-how in manufacturing space shuttle external tanks to develop liquefied natural gas (LNG) tanks, for storage and transportation at its Louisiana facility.

Tags: us natural martin develop

 

Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimers Disease

2013-03-13 13:30:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. & AUSTIN, Texas Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Mercks Lead Investigational Medicine for Alzheimers Disease WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). Language:  English Contact HTML:  Media Contacts:MerckCaroline Lappetito, 267-305-7639orLuminexMimi Torrington, 512-219-8020mtorrington@luminexcorp.comorInvestor Contacts:MerckCarol Ferguson, 908-423-4465orLuminexMatt Scalo, 512-336-3587mscalo@luminexcorp.com Ticker Slug:  Ticker: MRK Exchange: NYSE Ticker: LMNX Exchange: NASDAQ read more

Tags: support enter development program

 

Sites : [426] [427] [428] [429] [430] [431] [432] [433] [434] [435] [436] [437] [438] [439] [440] [441] [442] [443] [444] [445] next »